Table 4.
CRC death/ no. at risk | All CRC (n = 4365) | ||||
---|---|---|---|---|---|
HR | 95 % CI | p-value | |||
Site | Colon | 923/2847 | 1.00 | - | - |
Rectum | 487/1518 | 0.85 | 0.74-0.98 | 0.022 | |
Stage dukes | A | 55/933 | 1.00 | - | - |
B | 250/1438 | 2.97 | 2.21-3.99 | 0.000 | |
C | 520/1345 | 7.74 | 5.75-10.4 | 0.000 | |
D | 585/649 | 34.1 | 25.0-46.5 | 0.000 | |
Grade | Low | 10/114 | 1.00 | - | - |
Intermediate | 826/3137 | 1.22 | 0.72-2.07 | 0.453 | |
High | 405/825 | 2.25 | 1.32-3.84 | 0.003 | |
Unknown | 159/289 | 2.09 | 1.20-3.64 | 0.010 | |
Age group | 50-59 | 298/901 | 1.00 | - | - |
60-69 | 467/1552 | 1.04 | 0.89-1.21 | 0.600 | |
70-79 | 645/1942 | 1.12 | 0.96-1.29 | 0.146 | |
Sex | Female | 585/1867 | 1.00 | - | - |
Male | 825/2498 | 1.07 | 0.95-1.20 | 0.243 | |
Private Insurance | No | 686/1985 | 1.00 | - | - |
Yes | 724/2380 | 0.95 | 0.84-1.06 | 0.335 | |
Comorbidity | None | 941/3068 | 1.00 | - | - |
One (not severe) | 248/779 | 0.90 | 0.78-1.05 | 0.194 | |
Multiple / severe | 221/518 | 1.21 | 1.02-1.44 | 0.033 | |
SES quintile | Low | 382/1072 | 1.00 | - | - |
Low-mid | 280/878 | 0.94 | 0.80-1.11 | 0.443 | |
Middle | 246/791 | 0.93 | 0.78-1.10 | 0.379 | |
Mid-high | 276/843 | 1.06 | 0.90-1.25 | 0.508 | |
High | 226/781 | 0.75 | 0.62-0.91 | 0.004 | |
Residence | Urban | 1007/3102 | 1.00 | - | - |
Outer urban | 122/429 | 0.95 | 0.79-1.16 | 0.638 | |
Rural | 47/188 | 0.98 | 0.82-1.17 | 0.830 | |
Remote | 93/242 | 1.12 | 0.90-1.39 | 0.324 | |
Surgerya | No | 230/295 | 1.00 | - | - |
Yes | 1180/4070 | 0.51 | 0.42-0.62 | 0.000 | |
Radiotherapya | No | 1141/3757 | 1.00 | - | - |
Yes | 36/269 | 1.41 | 1.18-1.68 | 0.000 | |
Chemotherapya | No | 632/2745 | 1.00 | - | - |
Yes | 778/1620 | 0.87 | 0.76-1.00 | 0.047 | |
Diagnosis year | (continuous) | 1410/4365 | 0.95 | 0.92-0.98 | 0.002 |
CRC patients age 50-79 years diagnosed in South Australia 2003–3008
Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and approximately equivalent point estimates for all HRs)
aTreatments received within 12 months of diagnosis